What is Bambec 10mg?

This is an automatically translated article.

Bambec 10mg drug contains active ingredient Bambuterol, selective stimulant effect on beta-2 receptors to relax bronchial smooth muscle, inhibit edematous reactions and release endogenous spasmogenic substances. Let's learn the uses and notes when using Bambec 10mg through the article below.

1. What is Bambec 10mg? How does it work?

Bambec contains active ingredient Bambuterol 10mg, indicated in the following medical conditions:
Asthma; Chronic bronchitis, lung diseases with spasms, emphysema.

2. Pharmacology of the drug Bambec 10mg

Pharmacodynamics:
Bambec 10mg drug contains the active ingredient bambuterol - a precursor of terbutalin, which is a sympathomimetic agonist on beta-2 receptors, so it has the effect of relaxing bronchial smooth muscle, inhibiting the edema reaction, inhibits the release of endogenous constrictors and increases clearance of the mucinous cilia. Pharmacokinetics:
Absorption: Oral bioavailability of Bambuterol is approximately 20%. The extent to which the drug is absorbed is not affected when administered concomitantly with food. Maximum plasma concentrations of terbutaline, the active metabolite of the drug, are reached in 2 to 6 hours. The duration of action of the drug lasts at least 24 hours. During 4-5 days of treatment, the drug will reach steady state in plasma. Distribution: There are no reports on the distribution of the drug. Metabolism: 90% of the absorbed dose of Bambec is slowly metabolized by plasma cholinesterase hydrolysis and oxidation to the active form of terbutaline. About one third of the absorbed dose of Bambec is metabolised in the intestinal wall and liver to intermediate metabolites. In adults, approximately 10% of an oral dose of bambuterol is converted to terbutaline. Elimination: The half-life (t1/2) of Bambec is 13 hours, the half-life of the active metabolite - terbutalin is about 21 hours. Excretion of bambuterol and its active substances (including terbutaline) occurs via the kidneys, so patients with renal impairment (with creatinine clearance <50 mL/min) should be given a low starting dose. The drug is not recommended in patients with creatinine clearance < 30 mL/min. In patients with cirrhosis, drug metabolism may vary unpredictably from individual to individual.

3. Dosage of Bambuterol

Bambuterol 10mg is taken orally, use it right before going to bed. Dosage depends on the patient's condition, the general recommended dose is once a day. In many cases it is necessary to adjust the dose to suit the individual patient, the optimal combination of anti-inflammatory methods (such as inhaled corticosteroids, leukotriene antagonists) when using Bambec for maintenance treatment of asthma manage.
Adults: Initial dose is 10 - 20 mg, may increase dose from 10 mg to 20 mg after 1-2 weeks of treatment depending on clinical effect. For patients who have well tolerated β2 agonists, the recommended starting dose is the same as the maintenance dose; Elderly: No need to adjust the dose of Bambec used; Patients with impaired liver function: Bambec should not be used in patients with liver dysfunction because the metabolism of bambuterol to terbutaline cannot be predicted; Patients with moderate to severe renal impairment (GFR < 50ml/min): The recommended starting dose is half the adult dose; Children: Not recommended for use in children.

4. Note when using Bambec 10mg

General note if you are taking Bambec 10mg:
Bambec 10mg has a bronchial smooth muscle relaxant effect that is excreted by the kidneys, so it is necessary to adjust the dose and monitor in patients with impaired renal function (GFR ≤ ≤). 50ml/min). For patients with liver dysfunction, cirrhosis and impaired liver function due to many causes, when taking the drug, it is necessary to adjust the dose appropriately for each patient, assess the ability and extent of metabolism of the drug to terbutaline. Is there a decrease in the patient? Therefore, it is almost clinically recommended to use the active substance terbutaline in the treatment of these patients. Use caution in patients with thyrotoxicosis. Patients with heart diseases such as arrhythmia, myocardial ischemia, severe heart failure... who are being treated with Bambec drug should notify their doctor when symptoms of angina pectoris or heart disease progress. uglier. Bambuterol active ingredient of the drug is converted to terbutaline, do not use terbutaline as an antispasmodic in patients at risk of ischemic heart disease and patients with a history of ischemic heart disease. Use with caution in patients with acute severe asthma, because the risk of hypokalemia is increased with hypoxemia. The risk of hypokalemia may occur with combination therapy, so serum potassium levels should be monitored in these patients. Use caution in patients receiving digitalis glycoside therapy, because the risk of hypokalemia increases the possibility of digitalis toxicity. Patients with long-term asthma treated with β2 agonists should also receive optimal anti-inflammatory therapy such as leucotriene receptor antagonists, inhaled corticosteroids, etc. These patients should be counseled to maintain anti-inflammatory therapy after treatment. Treat with Bambec 10mg, even if symptoms have improved. If symptoms persist or require an increase in dose with a β2-agonist, it indicates worsening of the underlying medical condition and the patient should be reevaluated. Do not increase the dose of Bambec or use the drug in the starting dose for acute exacerbations. Bambec tablets contain lactose, so patients should not take the drug in case of rare hereditary conditions such as galactose intolerance, glucose-galactose malabsorption, complete lack of lactase enzyme. Use caution when using Bambec 10mg in patients with narrow-angle glaucoma. The use of Bambec 10mg is contraindicated in the following cases:
People who are sensitive to terbutalin or other ingredients in Bambec; Do not use the drug in the treatment of children due to limited clinical data in these subjects.

Effects of the drug on special subjects:
Pregnant women: Use caution when using the drug for pregnant women in the first 3 months. For β2 agonists formulated in the delayed release form, caution should be exercised in women in the late stages of pregnancy because of the drug's antispasmodic action. Premature infants born to mothers treated with Bambec may develop transient hypoglycemia. Lactation: There are currently no studies demonstrating whether Bambuterol or its metabolites cross the breast milk "barrier". Therefore, based on the benefits and risks, the treating physician will decide whether to discontinue breastfeeding or treat with Bambec. Drivers and machine operators: The drug does not affect drivers or machine operators.

5. Treatment of drug overdose

Overdose of Bambec 10mg will lead to increased terbutaline levels in the blood, patients may experience symptoms such as anxiety, headache, nausea, muscle tremors, cramps, tachycardia, palpitations, arrhythmia, hypotension...
Usually with mild overdoses, no treatment is needed. In case of severe overdose, the following treatment methods should be performed:
Gastric lavage with activated charcoal; Assess the patient's blood sugar, electrolytes and acid-base balance; Monitor heart rate and blood pressure level; Antidote of Bambec overdose requires the use of selective beta-blockers on the heart, but these drugs should be used with caution in patients with a history of bronchospasm.

6. Drug interactions

Bambec 10mg may interact with the following drugs:
Concurrent use of Bambec and Suxamethonium (succinylcholine) increases the muscle relaxant effect of Suxamethonium. It is caused by the enzyme that inactivates suxamethonium in the blood plasma, cholinesterase, which is partially inhibited by bambuterol. The degree of inhibition is dose dependent and reversible upon discontinuation of bambec. Beta-blockers, especially non-selective inhibitors, can completely or partially block the effects of beta-receptor agonists, including Bambec. Do not use halothane during treatment with Bambec or β2 agonists because of the increased risk of cardiac arrhythmias. Bambec in particular and β2 agonists in general cause hypokalemia, so caution should be taken when combining these drugs with serum potassium chelators such as diuretics, corticosteroids, methyl xanthin... Active ingredient concentrations In the drug Bambec is reduced when co-administered with quinidine because quinidine inhibits the enzyme cholinesterase even at therapeutic doses, so it should be used with caution in patients being treated with sympathomimetic drugs. In summary, Bambec 10mg is indicated in the pathological conditions of bronchial asthma, chronic bronchitis, lung diseases with spasms, emphysema. To ensure safety, during the use of the drug, if there are any prolonged abnormal signs, the patient should notify the doctor for appropriate treatment.

Please dial HOTLINE for more information or register for an appointment HERE. Download MyVinmec app to make appointments faster and to manage your bookings easily.